Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Aileron Therapeutics Announces Oral Presentation Of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles And Their Stem Cells From Chemotherapy-Induced Damage At The European Society For Dermatological Research Annual Meeting 2022

Author: Benzinga Newsdesk | September 30, 2022 08:43am
  • New ex vivo data demonstrates protection against cyclophosphamide-induced damage to hair follicles and their stem cells
     
  • Encore presentation of data presented at Society for Investigative Dermatology in May 2022 shows:
    • ALRN-6924 temporarily arrested the cell cycle in human scalp hair follicles and their stem cells
    • Ex vivo data demonstrated protection against taxane-induced damage to hair follicles and their stem cells
  • Nearly all breast cancer patients receiving neoadjuvant or adjuvant chemotherapy, including cyclophosphamide and taxanes, such as docetaxel, experience alopecia (hair loss)
  • Aileron is evaluating ALRN-6924 as a novel chemoprotective agent to prevent chemotherapy-induced bone marrow toxicities and alopecia in its ongoing Phase 1b breast cancer trial

Posted In: ALRN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

04/22/2024 Dick's Sporting Goods, Inc. (DKS)
04/22/2024 Innodata Inc. (INOD)
04/22/2024 Fox Factory Holding Corp. (FOXF)
04/23/2024 Lantronix, Inc. (LTRX)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)
CORE Finalist